Peer-influenced content. Sources you trust. No registration required. This is HCN.
Conexiant
The FDA approved enlicitide, the first oral PCSK9 inhibitor, after phase 3 studies demonstrated substantial LDL-C reductions in patients requiring additional lipid lowering. Cardiovascular outcomes data remain pending.
Cardiology July 23rd 2026
MDLinx
Synthetic DNA molecules known as polypurine reverse Hoogsteen hairpins reduced PCSK9 expression and lowered LDL cholesterol by approximately 50% in preclinical models, representing an early-stage gene-targeted approach distinct from existing monoclonal antibody and RNA interference strategies.
Cardiology June 2nd 2026
Medical Professionals Reference (MPR)
Lerochol (lerodalcibep-liga), a once-monthly self-administered PCSK9 inhibitor, is now commercially available as adjunctive LDL-C-lowering therapy for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
Cardiology May 19th 2026
Extreme LDL-C in young patients with family history points toward familial hypercholesterolemia, a common genetic disorder that remains undiagnosed in 70% of cases.
Cardiology May 5th 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS